Phase 3 Thyroid Cancer Trial, Recruiting (NCT05999630)

Phase 3 Thyroid Cancer Trial, Recruiting NCT05999630 Sponsor: Vanderbilt University Medical Center Condition: Thyroid Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT05999630 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Thyroid Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who are receiving radioiodine (radioactive iodine) treatment for thyroid cancer
People whose radioiodine treatment dose is 150 mCi or higher
People who are 18 years of age or older

Who may not be able to join:

People who use any eye drops other than plain artificial tears (lubricating drops)
People who have a history of injury to the area around the eye that affected the tear ducts or tear-producing glands
People who have a history of tear duct disease, such as infections or blockages of the tear drainage system
People who have previously received radiation therapy (radiotherapy) to any area
People who are currently using or have previously used certain chemotherapy medicines, such as 5-fluorouracil or docetaxel
People who have medical conditions known to affect or narrow the tear drainage duct, such as sarcoidosis, granulomatosis with polyangiitis, or chronic lymphocytic leukemia
People who already have a blocked tear drainage duct at the time of joining the trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 27 July 2026

Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 615-936-1639

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05999630

Sponsor: Vanderbilt University Medical Center

Phase: Phase 3

Status: Recruiting

Condition: Thyroid Cancer

Trial contact: 615-936-1639

More information: https://clinicaltrials.gov/study/NCT05999630

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who are receiving radioiodine (radioactive iodine) treatment for thyroid cancer
People whose radioiodine treatment dose is 150 mCi or higher
People who are 18 years of age or older

Who may not be able to join:

People who use any eye drops other than plain artificial tears (lubricating drops)
People who have a history of injury to the area around the eye that affected the tear ducts or tear-producing glands
People who have a history of tear duct disease, such as infections or blockages of the tear drainage system
People who have previously received radiation therapy (radiotherapy) to any area
People who are currently using or have previously used certain chemotherapy medicines, such as 5-fluorouracil or docetaxel
People who have medical conditions known to affect or narrow the tear drainage duct, such as sarcoidosis, granulomatosis with polyangiitis, or chronic lymphocytic leukemia
People who already have a blocked tear drainage duct at the time of joining the trial

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 27 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 3

Sponsor

Vanderbilt University Medical Center

Registry

ClinicalTrials.gov

Start date

21 August 2023

Est. completion

31 December 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Incidence of Post-Radiotherapy Nasolacrimal Duct Obstruction (NLDO)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov